

Linzess® (linaclotide) - New indication

- On June 12, 2023, <u>Ironwood Pharmaceuticals announced</u> the <u>FDA approval</u> of <u>Linzess</u> (<u>linaclotide</u>), for the treatment of functional constipation (FC) in pediatric patients 6 to 17 years of age.
- Linzess is the first FDA-approved prescription therapy for FC in this patient population.
- Linzess is also approved for the treatment of irritable bowel syndrome with constipation in adults and chronic idiopathic constipation in adults.
- The approval of Linzess for the new indication was based on a randomized, double-blind, placebo-controlled study in 328 pediatric patients 6 to 17 years of age with FC. Patients received Linzess or placebo. The primary endpoint was the 12-week change from baseline in spontaneous bowel movements (SBM) frequency rate.
 - The least squares 12-week mean change from baseline in SBM frequency rate was 2.6 with Linzess and 1.3 with placebo (treatment difference 1.3, 95% CI: 0.7, 1.8).
- Linzess carries a boxed warning for risk of serious dehydration in pediatric patients less than 2 years of age.
- The most common adverse reaction (≥ 2%) with Linzess use in pediatric patients 6 to 17 years of age with FC is diarrhea.
- The recommended dose of Linzess for the treatment of FC in pediatric patients is 72 mcg orally once daily.
 - Refer to the Linzess drug label for dosing for its other indications.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.